Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...

This obesity-focused biopharmaceutical company just had an initial public offering, and these buyers helped themselves to some of those Metsera Inc. (NASDAQ: MTSR) shares. Last month, the company ...

After hours: February 13 at 5:32:04 PM EST Loading Chart for EWTX ...

Dyne Therapeutics Inc.-5.60% $1.56B ...

Before the Telethon Foundation assumed responsibility for the therapy, it was licensed to Orchard Therapeutics – a biotech specialising in gene therapies for rare diseases. However, in 2022, Orchard ...